NASDAQ:SANA Sana Biotechnology (SANA) Stock Price, News & Analysis $4.95 -0.18 (-3.51%) Closing price 04:00 PM EasternExtended Trading$4.97 +0.02 (+0.40%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Sana Biotechnology Stock (NASDAQ:SANA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Sana Biotechnology alerts:Sign Up Key Stats Today's Range$4.72▼$5.2050-Day Range$1.68▼$5.1452-Week Range$1.26▼$7.30Volume5.32 million shsAverage Volume5.86 million shsMarket Capitalization$1.12 billionP/E RatioN/ADividend YieldN/APrice Target$9.17Consensus RatingBuy Company Overview Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington. Read More Sana Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreSANA MarketRank™: Sana Biotechnology scored higher than 64% of companies evaluated by MarketBeat, and ranked 386th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingSana Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSana Biotechnology has only been the subject of 2 research reports in the past 90 days.Read more about Sana Biotechnology's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sana Biotechnology are expected to grow in the coming year, from ($1.16) to ($0.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sana Biotechnology is -5.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sana Biotechnology is -5.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSana Biotechnology has a P/B Ratio of 4.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Sana Biotechnology's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted29.92% of the float of Sana Biotechnology has been sold short.Short Interest Ratio / Days to CoverSana Biotechnology has a short interest ratio ("days to cover") of 8.4.Change versus previous monthShort interest in Sana Biotechnology has recently decreased by 13.84%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSana Biotechnology does not currently pay a dividend.Dividend GrowthSana Biotechnology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted29.92% of the float of Sana Biotechnology has been sold short.Short Interest Ratio / Days to CoverSana Biotechnology has a short interest ratio ("days to cover") of 8.4.Change versus previous monthShort interest in Sana Biotechnology has recently decreased by 13.84%, indicating that investor sentiment is improving significantly. News and Social Media2.5 / 5News Sentiment0.47 News SentimentSana Biotechnology has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.06 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Sana Biotechnology this week, compared to 7 articles on an average week.Search Interest25 people have searched for SANA on MarketBeat in the last 30 days. This is an increase of 213% compared to the previous 30 days.MarketBeat Follows12 people have added Sana Biotechnology to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sana Biotechnology insiders have not sold or bought any company stock.Percentage Held by Insiders30.10% of the stock of Sana Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.23% of the stock of Sana Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sana Biotechnology's insider trading history. Receive SANA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sana Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address SANA Stock News HeadlinesCiti Maintained a Buy Rating on Sana Biotechnology (SANA)July 23 at 2:49 PM | msn.comSana Biotechnology, Inc. (SANA) Secures an Overweight Rating from Morgan StanleyJuly 11, 2025 | finance.yahoo.comGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.July 25 at 2:00 AM | Stansberry Research (Ad)Sana Reports Promising Diabetes Cell Therapy Data at ADA MeetingJuly 4, 2025 | msn.comSana Biotechnology (SANA) Stock Surges on Positive Type 1 Diabetes Treatment ResultsJune 29, 2025 | insidermonkey.comSana Biotechnology’s SWOT analysis: promising cell therapy stock faces crowded market - Investing.comJune 26, 2025 | investing.comSana Biotechnology (SANA) Receives a Buy from Citizens JMPJune 26, 2025 | theglobeandmail.comBofA Remains Bullish on Sana Biotechnology (SANA)June 24, 2025 | insidermonkey.comSee More Headlines SANA Stock Analysis - Frequently Asked Questions How have SANA shares performed this year? Sana Biotechnology's stock was trading at $1.63 at the beginning of the year. Since then, SANA stock has increased by 203.7% and is now trading at $4.95. How were Sana Biotechnology's earnings last quarter? Sana Biotechnology, Inc. (NASDAQ:SANA) issued its earnings results on Thursday, May, 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.02. When did Sana Biotechnology IPO? Sana Biotechnology (SANA) raised $322 million in an IPO on Thursday, February 4th 2021. The company issued 15,000,000 shares at $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and BofA Securities acted as the underwriters for the IPO. Who are Sana Biotechnology's major shareholders? Top institutional shareholders of Sana Biotechnology include CWM LLC (0.04%), Palumbo Wealth Management LLC (0.04%), Wealth Enhancement Advisory Services LLC (0.02%) and Pallas Capital Advisors LLC (0.02%). Insiders that own company stock include Robert Nelsen, Fmr Llc, Richard Mulligan, Ventures Fund V Gener Flagship and Joshua H Bilenker. View institutional ownership trends. How do I buy shares of Sana Biotechnology? Shares of SANA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sana Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sana Biotechnology investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Walmart (WMT). Company Calendar Last Earnings5/08/2025Today7/25/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SANA CIK1770121 Websana.com Phone206-701-7914FaxN/AEmployees380Year FoundedN/APrice Target and Rating Average Price Target for Sana Biotechnology$9.17 High Price Target$15.00 Low Price Target$5.00 Potential Upside/Downside+85.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$266.76 million Net MarginsN/A Pretax MarginN/A Return on Equity-86.58% Return on Assets-44.49% Debt Debt-to-Equity RatioN/A Current Ratio3.40 Quick Ratio3.40 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.12 per share Price / Book4.42Miscellaneous Outstanding Shares225,480,000Free Float157,608,000Market Cap$1.12 billion OptionableOptionable Beta1.86 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:SANA) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sana Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sana Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.